AnalystsSerge BelangerSerge Belanger's Stock Forecasts
AnalystsSerge Belanger
Analyst Ranking
Top 7%
#315 out of 4922 analysts
Average Return
+6.13%
Win Rate
46%165 out of 358
Risk vs Reward
Poor
Good
Serge Belanger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Cormedix IncCRMD | +230.33% | $3.33 | $11.00 | 2023-11-15 - 2024-11-14 | Buy |
Cormedix IncCRMD | +209.65% | $3.42 | $10.59 | 2024-03-12 - 2025-03-11 | Buy |
Liquidia CorpLQDA | +176.08% | $2.55 | $7.04 | 2021-03-23 - 2022-03-22 | Buy |
Serge Belanger Analyst Color
Get additional color on Serge Belanger's coverage of popular stocks
Serge Belanger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biocryst Pharmaceuticals IncBCRX | 15 | Buy | $17.00 | +81.62% | Reiterates | 3 days ago |
Cormedix IncCRMD | 18 | Buy | $20.00 | +60.00% | Maintains | 7 days ago |
Newamsterdam Pharma Co NvNAMS | 9 | Buy | $40.00 | +115.40% | Reiterates | 19 days ago |
Liquidia CorpLQDA | 31 | Buy | $32.00 | +144.27% | Maintains | a month ago |
Arcutis Biotherapeutics IncARQT | 21 | Buy | $20.00 | +45.56% | Reiterates | a month ago |
Viridian Therapeutics IncVRDN | 17 | Buy | $36.00 | +151.22% | Reiterates | a month ago |
Trevi Therapeutics IncTRVI | 19 | Buy | $24.00 | +327.05% | Reiterates | a month ago |
Clearside Biomedical IncCLSD | 15 | Buy | $3.00 | +289.61% | Maintains | 2 months ago |
Cytokinetics IncCYTK | 23 | Buy | $72.00 | +117.13% | Reiterates | 2 months ago |
Moonlake ImmunotherapeuticsMLTX | 12 | Buy | $66.00 | +38.89% | Reiterates | 2 months ago |
Xenon Pharmaceuticals IncXENE | 12 | Buy | $55.00 | +69.75% | Maintains | 2 months ago |
Pacira Biosciences IncPCRX | 27 | Buy | $30.00 | +27.77% | Maintains | 2 months ago |
Evolus IncEOLS | 15 | Buy | $22.00 | +140.70% | Reiterates | 2 months ago |
Esperion Therapeutics IncESPR | 20 | Buy | $4.00 | +302.41% | Maintains | 2 months ago |
Ocular Therapeutix IncOCUL | 3 | Buy | $14.00 | +51.84% | Maintains | 2 months ago |
Heron Therapeutics IncHRTX | 20 | Buy | $4.00 | +86.92% | Reiterates | 3 months ago |
Collegium Pharmaceutical IncCOLL | 21 | Buy | $46.00 | +53.69% | Reiterates | 3 months ago |
Kalvista Pharmaceuticals IncKALV | 18 | Buy | $28.00 | +145.40% | Reiterates | 3 months ago |
Verrica Pharmaceuticals IncVRCA | 14 | Hold | $12.00 | +2,194.46% | Downgrades | 9 months ago |
Revance Therapeutics IncRVNC | 16 | Buy | $12.00 | +228.77% | Reiterates | a year ago |
Dice Therapeutics IncDICE | 1 | Buy | $56.00 | N/A | Reiterates | 2 years ago |
Tricida IncTCDAQ | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Phasebio Pharmaceuticals IncPHASQ | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Aerie Pharmaceuticals IncAERI | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 4 | Hold | N/A | N/A | Downgrades | 3 years ago |
Akebia Therapeutics IncAKBA | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Zogenix IncZGNX | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Flexion Therapeutics IncFLXN | 1 | Buy | $18.00 | N/A | Maintains | 4 years ago |
Calcimedica IncCALC | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Hold | N/A | N/A | Downgrades | 4 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.